Exo-s-mecamylamine formulation and use in treatment
AssigneeTargacept, Inc.
InventorsDouglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
Life of this patent
Estimating the term…
Loading patent…
AssigneeTargacept, Inc.
InventorsDouglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
Estimating the term…
A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.
An oral pharmaceutical composition for better symptom control and fewer side effects compared to racemic mecamylamine comprising:
Dependencies are inferred from the claim text.